Veru targets Phase 3 enobosarm trials following promising Phase 2b results in obesity treatment
Q1 2025 Management View Veru highlighted its transformation into a late clinical-stage biopharmaceutical company focusing on cardiometabolic and inflammatory diseases, with major developments in ...
11,000 Years of Designer Sheep
According to a new exhibition in Amsterdam, centuries of human intervention turned the animal into “a wool-producing machine ...
BioSpace17h
Roche’s Evrysdi Becomes First Pill Cleared for Spinal Muscular Atrophy
The FDA on Wednesday approved the industry’s first-ever tablet treatment for spinal muscular atrophy— Roche ’s SMN2 splicing ...